Matches in SemOpenAlex for { <https://semopenalex.org/work/W2729249879> ?p ?o ?g. }
- W2729249879 abstract "We describe a randomized, non-blinded Phase II interventional study to assess the safety and efficacy of stereotactic ablative radiotherapy (SABR) for hormone-sensitive oligometastatic prostate adenocarcinoma, and to describe the biology of the oligometastatic state using immunologic, cellular, molecular, and functional imaging correlates. 54 men with oligometastatic prostate adenocarcinoma will be accrued. The primary clinical endpoint will be progression at 6 months from randomization with the hypothesis that SABR to all metastases will forestall progression by disrupting the metastatic process. Secondary clinical endpoints will include local control at 6 months post-SABR, toxicity and quality of life, and androgen deprivation therapy (ADT)-free survival (ADT-FS). Further fundamental analysis of the oligometastatic state with be achieved through correlation with investigational 18F–DCFPyL PET/CT imaging and measurement of circulating tumor cells, circulating tumor DNA, and circulating T-cell receptor repertoires, facilitating an unprecedented opportunity to characterize, in isolation, the effects of SABR on the dynamics of and immunologic response to oligometastatic disease. Patients will be randomized 2:1 to SABR or observation with minimization to balance assignment by primary intervention, prior hormonal therapy, and PSA doubling time. Progression after 6 months will be compared using Fisher’s exact test. Hazard ratios and Kaplan-Meier estimates of progression free survival (PFS), ADT free survival (ADT-FS), time to locoregional progression (TTLP) and time to distant progression (TTDP) will be calculated based on an intention-to-treat. Local control will be assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Withdrawal from the study prior to 6 months will be counted as progression. Adverse events will be summarized by type and grade. Quality of life pre- and post- SABR will be measured by Brief Pain Inventory. The ORIOLE trial is the first randomized, non-blinded Phase II interventional study in the North America evaluating the safety and efficacy of SABR in oligometastatic hormone-sensitive prostate cancer. Leading-edge laboratory and imaging correlates will provide unique insight into the effects of SABR on the oligometastatic state. ClinicalTrials.gov Identifier: NCT02680587. URL of Registry: https://clinicaltrials.gov/show/NCT02680587 Date of Registration: 02/08/2016. Date of First Participant Enrollment: 05/23/2016." @default.
- W2729249879 created "2017-07-14" @default.
- W2729249879 creator A5001771354 @default.
- W2729249879 creator A5001783218 @default.
- W2729249879 creator A5001873561 @default.
- W2729249879 creator A5002414848 @default.
- W2729249879 creator A5011710591 @default.
- W2729249879 creator A5012074439 @default.
- W2729249879 creator A5018645768 @default.
- W2729249879 creator A5039646183 @default.
- W2729249879 creator A5040778833 @default.
- W2729249879 creator A5049018134 @default.
- W2729249879 creator A5049568817 @default.
- W2729249879 creator A5054386630 @default.
- W2729249879 creator A5055949265 @default.
- W2729249879 creator A5067187971 @default.
- W2729249879 creator A5070623757 @default.
- W2729249879 creator A5071268553 @default.
- W2729249879 creator A5080102032 @default.
- W2729249879 creator A5080403309 @default.
- W2729249879 creator A5087520734 @default.
- W2729249879 creator A5088048189 @default.
- W2729249879 date "2017-06-29" @default.
- W2729249879 modified "2023-09-26" @default.
- W2729249879 title "A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)" @default.
- W2729249879 cites W1965842207 @default.
- W2729249879 cites W1973646515 @default.
- W2729249879 cites W1988871494 @default.
- W2729249879 cites W1997224430 @default.
- W2729249879 cites W1998726546 @default.
- W2729249879 cites W1999070529 @default.
- W2729249879 cites W2010255370 @default.
- W2729249879 cites W2014771865 @default.
- W2729249879 cites W2015595599 @default.
- W2729249879 cites W2020465877 @default.
- W2729249879 cites W2039467075 @default.
- W2729249879 cites W2049119588 @default.
- W2729249879 cites W2051021899 @default.
- W2729249879 cites W2053554578 @default.
- W2729249879 cites W2058825665 @default.
- W2729249879 cites W2069976078 @default.
- W2729249879 cites W2071879495 @default.
- W2729249879 cites W2097593062 @default.
- W2729249879 cites W2098599714 @default.
- W2729249879 cites W2100374144 @default.
- W2729249879 cites W2106893486 @default.
- W2729249879 cites W2107814019 @default.
- W2729249879 cites W2112097252 @default.
- W2729249879 cites W2115646671 @default.
- W2729249879 cites W2127240958 @default.
- W2729249879 cites W2127407300 @default.
- W2729249879 cites W2131372578 @default.
- W2729249879 cites W2132892424 @default.
- W2729249879 cites W2136706275 @default.
- W2729249879 cites W2138198077 @default.
- W2729249879 cites W2143744080 @default.
- W2729249879 cites W2147136637 @default.
- W2729249879 cites W2167331614 @default.
- W2729249879 cites W2507354747 @default.
- W2729249879 cites W2511755939 @default.
- W2729249879 cites W4240340450 @default.
- W2729249879 cites W50507632 @default.
- W2729249879 doi "https://doi.org/10.1186/s12885-017-3455-6" @default.
- W2729249879 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5492934" @default.
- W2729249879 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28662647" @default.
- W2729249879 hasPublicationYear "2017" @default.
- W2729249879 type Work @default.
- W2729249879 sameAs 2729249879 @default.
- W2729249879 citedByCount "75" @default.
- W2729249879 countsByYear W27292498792017 @default.
- W2729249879 countsByYear W27292498792018 @default.
- W2729249879 countsByYear W27292498792019 @default.
- W2729249879 countsByYear W27292498792020 @default.
- W2729249879 countsByYear W27292498792021 @default.
- W2729249879 countsByYear W27292498792022 @default.
- W2729249879 countsByYear W27292498792023 @default.
- W2729249879 crossrefType "journal-article" @default.
- W2729249879 hasAuthorship W2729249879A5001771354 @default.
- W2729249879 hasAuthorship W2729249879A5001783218 @default.
- W2729249879 hasAuthorship W2729249879A5001873561 @default.
- W2729249879 hasAuthorship W2729249879A5002414848 @default.
- W2729249879 hasAuthorship W2729249879A5011710591 @default.
- W2729249879 hasAuthorship W2729249879A5012074439 @default.
- W2729249879 hasAuthorship W2729249879A5018645768 @default.
- W2729249879 hasAuthorship W2729249879A5039646183 @default.
- W2729249879 hasAuthorship W2729249879A5040778833 @default.
- W2729249879 hasAuthorship W2729249879A5049018134 @default.
- W2729249879 hasAuthorship W2729249879A5049568817 @default.
- W2729249879 hasAuthorship W2729249879A5054386630 @default.
- W2729249879 hasAuthorship W2729249879A5055949265 @default.
- W2729249879 hasAuthorship W2729249879A5067187971 @default.
- W2729249879 hasAuthorship W2729249879A5070623757 @default.
- W2729249879 hasAuthorship W2729249879A5071268553 @default.
- W2729249879 hasAuthorship W2729249879A5080102032 @default.
- W2729249879 hasAuthorship W2729249879A5080403309 @default.
- W2729249879 hasAuthorship W2729249879A5087520734 @default.
- W2729249879 hasAuthorship W2729249879A5088048189 @default.
- W2729249879 hasBestOaLocation W27292498791 @default.
- W2729249879 hasConcept C106159729 @default.
- W2729249879 hasConcept C121608353 @default.